BridgeBio Pharma (BBIO) Asset Utilization Ratio (2021 - 2026)

BridgeBio Pharma has disclosed Asset Utilization Ratio across 6 years of filings, most recently posting 0.5 for Q1 2026.

• Asset Utilization Ratio for Q1 2026 came in at 0.5, up 255.33% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.5 (up 255.33% YoY), and the FY2025 annual result was 0.54, up 78.74% from the prior year.
• Asset Utilization Ratio came in at 0.5 for Q1 2026 at BridgeBio Pharma, down from 0.52 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.52 in Q4 2025 to a low of 0.01 in Q2 2023.
• The 5-year median for Asset Utilization Ratio is 0.14 (2025), against an average of 0.2.
• Across the five-year window, Asset Utilization Ratio slumped 90.41% in 2023 and soared 2552.92% in 2024, its largest moves.
• BridgeBio Pharma's Asset Utilization Ratio stood at 0.11 in 2022, then slumped by 86.52% to 0.02 in 2023, then surged by 1708.76% to 0.28 in 2024, then jumped by 85.32% to 0.52 in 2025, then retreated by 3.15% to 0.5 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.5 (Q1 2026), 0.52 (Q4 2025), and 0.34 (Q3 2025), per Business Quant data.